Indicative drug-only band: USD 373,000 per one-time infusion. Delivered quote within 24h.Get my quote

How to access Yescarta from the UAE, the cross-border CAR-T pathway, 2026

Name: How to access Yescarta from the UAE, the cross-border CAR-T pathway, 2026
Published: 2026-05-13

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-13.

An Emirati patient with relapsed or refractory large B-cell lymphoma (LBCL) in the second-line or later setting, including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, or with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, may receive a recommendation for Yescarta (axicabtagene ciloleucel) from their treating hematologist. Yescarta is FDA-approved in the United States and manufactured by Kite Pharma, a Gilead Company. Yescarta is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. This is important: Yescarta is not a ready-to-ship medicine. It is manufactured from the patient's own T-cells, which must be collected by leukapheresis at a Yescarta-certified treatment center and then engineered at the Kite manufacturing facility before being returned for infusion. That makes the cross-border pathway materially different from a conventional named-patient drug import.

This guide explains how the pathway actually works, what documentation your hematologist needs, indicative cost and timing, and where Reserve Meds fits in.

The clinical situation

Yescarta is an autologous CD19-directed CAR T-cell product. The treatment course involves: leukapheresis at a Yescarta-certified center to collect autologous T-cells; cryopreservation and shipment to the Kite manufacturing facility; CAR-T cell engineering and expansion over approximately 2 to 3 weeks; return shipment of the patient-specific product; lymphodepleting chemotherapy (typically fludarabine and cyclophosphamide) in the days before infusion; infusion of the CAR T-cell product; and inpatient monitoring with discharge criteria typically requiring the patient to remain within 2 hours of the treatment center for 4 weeks post-infusion. The FDA boxed warning covers cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), both of which can be severe or life-threatening. Yescarta is dispensed only under the Yescarta and Tecartus REMS program in the US. Your hematologist will discuss the risk-benefit profile, the requirement for a certified center, and the practical logistics before initiating therapy.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How does this work across borders?

Because Yescarta is an autologous cell therapy that requires a Yescarta-certified center for both the leukapheresis collection and the infusion, the standard cross-border access pathway is patient travel to a US Yescarta-certified center, not import of a drug into the Kingdom of the UAE. The UAE Ministry of Health and Prevention (MoHAP) named-patient framework does support import of medicines, but CAR-T cellular products are practically delivered via patient travel to a certified treatment facility under that facility's REMS-compliant protocol.

Reserve Meds can help coordinate the referral arc to a US Yescarta-certified center (academic medical centers with CAR-T programs across the US), help your hematologist assemble the referral package, and coordinate the family logistics around the multi-week stay. We do not perform the leukapheresis, we do not manufacture the product, and we do not provide the infusion. Those are functions of the US treatment center under its FDA REMS authorisation.

How the pathway works, step by step

Consultation with your treating hematologist in the UAE. The recommendation for CAR-T is clinical, based on relapse pattern, prior lines (including any prior CAR-T or transplant), and fitness for the regimen. Your hematologist documents this rationale.
Referral package to a US Yescarta-certified center. Pathology, imaging, prior-therapy summary, performance status, organ function panel, and infectious disease screening are assembled into a referral package.
US center evaluation. The US center reviews the package, accepts the referral (or asks for additional workup), and schedules the leukapheresis collection.
Patient travel and leukapheresis. The patient travels to the US center for collection. Reserve Meds coordinates travel, accommodations, and a designated caregiver presence requirement.
Manufacturing. The collected cells ship to the Kite manufacturing facility. Engineering and quality release take approximately 2 to 3 weeks.
Lymphodepletion and infusion. The patient receives lymphodepleting chemotherapy, then the CAR T-cell infusion at the certified center, with inpatient monitoring for CRS and ICANS.
Post-infusion monitoring. The patient remains within 2 hours of the treatment center for approximately 4 weeks post-infusion, then transitions to ongoing follow-up coordinated between the US center and the UAE hematologist.

What documentation your hematologist needs

Your hematologist will typically need to assemble:

A clinical summary letter confirming diagnosis (LBCL or FL subtype, prior lines, prior CAR-T or transplant status), relapse pattern, and Yescarta as the recommended next step
Pathology reports including CD19 expression status
Imaging (PET/CT preferred) within recent timeframe
Organ function panel (CBC, CMP, LDH, LFTs), echocardiogram, pulmonary function tests
Infectious disease screening (HIV, HBV, HCV, CMV serologies)
Performance status documentation (typically ECOG 0-1 for CAR-T eligibility)
Confirmation that the patient has a designated caregiver who can accompany them for the duration of US treatment

Reserve Meds provides a CAR-T referral kit that bundles what US Yescarta-certified centers expect to see in a complete referral package.

Typical costs and indicative timing

Reserve Meds gives you a transparent reference range and an itemised quote at intake. As an illustrative composite case, the US cash-pay reference range for the Yescarta product itself sits in an indicative 2026 band of roughly USD 460,000 to 510,000. The treatment center facility and physician fees, lymphodepletion, inpatient monitoring, complication management, and post-infusion follow-up add substantially more, often bringing the total course cost to USD 700,000 to 1,000,000 or higher. Travel, accommodations, caregiver presence, and the multi-week stay are additional. Reserve Meds itemises each component in the delivered quote at intake.

Indicative timing from referral acceptance to infusion is typically 4 to 8 weeks: 1 to 2 weeks to schedule and complete the patient travel and leukapheresis, 2 to 3 weeks for manufacturing, and 1 week for lymphodepletion and infusion. The post-infusion stay in the US is approximately 4 additional weeks.

CAR-T cases require additional vetting given the clinical complexity and cost profile.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Yescarta specifically, we provide:

Referral coordination. We work with your the UAE hematologist to identify candidate Yescarta-certified centers and route the referral package.
Documentation. Referral package assembly aligned with US center intake requirements.
Travel and logistics. Coordination of patient and caregiver travel, accommodation near the treatment center, and the multi-week stay.
Concierge case lead. A named point of contact for the family across the full case arc.

Reserve Meds coordination fee for this pathway.

A flat concierge fee of USD 15,000 to 35,000 per case, scaled to the complexity of the pre-trip, in-US, and post-trip coordination required. The fee covers candidate US-certified center selection, referral package assembly and routing, pre-trip clinical workup and records transmission, financial-clearance coordination with the receiving center, visa and travel logistics for the patient and caregiver, in-US transport and translator support where needed, and post-trip clinical follow-up coordination back to the treating hematologist for 6 to 12 months.

The fee is paid directly to Reserve Meds. The CAR-T product cost, the US treatment-center charges, and any third-party travel and accommodation expenses are paid by the patient or family directly to the relevant counterparty. Reserve Meds does not mark up the center or the manufacturer, and Reserve Meds does not receive a referral fee from the center for the first patient cohort.

An itemised quote is issued at intake. Cash-pay only. No insurance billed.

We are a coordinator. We are not the prescriber, not a US treatment center, not the manufacturer of the cellular product, and not an oncology provider. The US treatment center is the clinical entity providing CAR-T under its FDA REMS authorisation. Reserve Meds operates on cash-pay only and does not bill insurance.

Frequently asked

Is this legal? Yes. Patient travel to a US-certified CAR-T center is a long-established pathway used by international patients across many programs. Reserve Meds operates as the coordination layer, not the clinical provider.

Can I get Yescarta in the UAE instead? CAR-T programs are increasingly available at major the UAE tertiary centers (Sheikh Shakhbout Medical City (SSMC), Cleveland Clinic Abu Dhabi, Tawam Hospital Al Ain, American Hospital Dubai, and Mediclinic City Hospital). If your hematologist concludes a local certified CAR-T option is appropriate, that is typically the simpler pathway. Reserve Meds is most useful when the local option is not available, not stocked, or your case requires a US specialist evaluation.

What about the boxed warning for CRS and ICANS? Cytokine release syndrome and neurotoxicity are managed by the certified treatment center under its REMS-compliant protocol with inpatient monitoring, tocilizumab and steroid availability, and ICU access. Your hematologist and the US treatment team perform that clinical management. Reserve Meds does not.

Will my private health insurance cover this? Cash-pay is the default posture. Some UAE private insurers and CCHI-aligned plans review CAR-T case-by-case on a pre-authorisation basis when the documentation package is strong. We supply documentation for your submission but do not process insurance claims.

What if I cannot travel to the US? Then cross-border Yescarta access is not feasible via this pathway, and your hematologist should explore locally available CAR-T programs, bispecific antibody alternatives (Columvi, Epkinly), or other regimens. Reserve Meds will tell you that directly rather than charge for a service that cannot deliver.

Next step

CAR-T cases require additional clinical and logistical vetting.

Start your Yescarta case Or message us on WhatsApp

Composite case examples. This content is for general information and does not constitute medical advice. CAR-T cellular therapy is a complex multi-step care arc; Reserve Meds is a coordination layer, not the clinical provider.

Regulatory status of Yescarta in United Arab Emirates, 2026

Yescarta (axicabtagene ciloleucel) is not currently held on the locally registered medicines list of the Ministry of Health and Prevention (MOHAP). The product is approved by the US Food and Drug Administration per the labelled indication of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (see the FDA label at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu).

Because Yescarta is not on the MOHAP locally registered list, access for a United Arab Emirates-based patient runs through the named-patient and personal-import framework that the MOHAP maintains for reference-authority-approved medicines that are not held locally. The official MOHAP portal is at mohap.gov.ae. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies); no locally available alternative is clinically equivalent for the specific patient indication; the treating physician of record takes documented clinical responsibility; and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility.

The named-patient and personal-import pathway is the routine framework. For a complex cell or gene therapy that requires a US-certified treatment center, the practical route is patient travel to that certified center rather than import into United Arab Emirates; see Block 2 below for the operational shape on that case type.

Tertiary centers and clinical coordination in United Arab Emirates

The United Arab Emirates tertiary referral network for a Yescarta case is concentrated at Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakhbout Medical City (SSMC), and Tawam Hospital. These centers carry the haematology, oncology, paediatric subspecialty, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For cellular and gene therapies that require leukapheresis collection, AAV infusion, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.

For cell and gene therapies specifically, the practical access pathway runs through patient travel to a US-certified treatment center (Casgevy authorised treatment centers, Yescarta certified centers, Abecma certified centers, Zolgensma certified centers, Elevidys treatment centers, Hemgenix treatment centers, and so on) rather than import of the cellular or AAV product into United Arab Emirates. The tertiary United Arab Emirates centers handle the upstream referral package assembly (clinical summary, pathology, imaging, organ function panel, infectious disease screen, performance status), the US-side coordination, and the long-term follow-up after the patient returns home. Reserve Meds coordinates the cross-border arc between the United Arab Emirates tertiary team and the US treatment center, including travel and accommodation logistics, financial clearance, and post-treatment data flow.

For oral kinase inhibitors and antibody therapies that can be administered in United Arab Emirates once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule.

United Arab Emirates pricing reference and payer posture, 2026

Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once your treating physician's documentation is in. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only range for Yescarta sits at approximately USD 400,000 to USD 450,000 per one-time autologous CAR-T infusion (US wholesale acquisition cost; total course inclusive of facility commonly USD 800,000 to 1,200,000). In AED terms at the 2026 reference rate of 1 USD = 3.670 AED, that translates to a drug-only band of approximately AED 1,468,000 to AED 1,651,500.

Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, US treatment center facility and physician fees where applicable (for cellular and gene therapies, the facility cost commonly equals or exceeds the product cost), Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a cell or gene therapy case the total course cost in 2026 commonly lands at 1.5x to 2.5x the drug-only band once US treatment center fees, lymphodepletion or pre-infusion conditioning, inpatient monitoring, complication management, and family travel and accommodation are added in.

Payer posture in United Arab Emirates is overwhelmingly cash-pay for named-patient imports and cross-border CAR-T cases. Public coverage (DHA Dubai Health Authority and DoH Abu Dhabi insurance schemes) generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.

Access barriers and how Reserve Meds clears them

The five access barriers we see most often for a Yescarta case in United Arab Emirates are: (1) Regulatory documentation complexity. The MOHAP named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format MOHAP reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Yescarta from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.

(3) For cell and gene therapies, the US-certified treatment center qualification gate. Casgevy, Yescarta, Carvykti, Abecma, Zolgensma, Elevidys, Hemgenix, and Luxturna can only be administered at a manufacturer-certified treatment center. Reserve Meds maintains the referral arcs to the appropriate US-certified centers and handles the referral package routing, financial clearance, and the multi-week stay coordination. (4) Family logistics. Patient and caregiver travel, accommodation near the treatment center, in-US transport, translator support where needed, and post-treatment data flow back to the treating United Arab Emirates physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.

Drug-specific clinical context for Yescarta: the labelled indication is relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. The relevant clinical-practice guideline body is National Comprehensive Cancer Network (NCCN) B-cell lymphoma guidelines at www.nccn.org. Your treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.

Recent regulatory and access news for Yescarta in United Arab Emirates, 2026

The Ministry of Health and Prevention (MOHAP) portal at mohap.gov.ae has not posted a Yescarta-specific listing on the publicly searchable locally registered medicines list at mohap.gov.ae/en/services/medicine-search as of 2026-06-04. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages have not registered a Yescarta-specific safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication remains relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (see the current label at accessdata.fda.gov). Kite Pharma, a Gilead Company continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The National Comprehensive Cancer Network (NCCN) B-cell lymphoma guidelines guidance at www.nccn.org remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.